Table 2.
High-performance liquid chromatography testing results (75%–125% active pharmaceutical ingredient [API] range) by formulation and presence of the Affordable Medicines Facility – malaria (AMFm) logo
| Presence of logo | Artesunate-amodiaquine fixed-dose combination and co-blister [% (n)] | Artemether-lumefantrine fixed-dose combination [% (n)] | Dihydroartemisinin-piperaquine co-blister [% (n)] | Dihydroartemisinin monotherapy [% (n)] | Artesunate monotherapy [% (n)] | Total [% (n)] |
|---|---|---|---|---|---|---|
| Non-AMFm drugsa outside API range | ||||||
| Accra | 75% (3/4) | 7.7% (1/13) | 100% (2/2) | 0% (0/5) | 100% (2/2) | 30.8% (8/26) |
| Lagos | N/A | N/A | N/A | N/A | 50% (10/20) | 50% (10/20) |
| Total | 75% (3/4) | 7.7% (1/13) | 100% (2/2) | 0% (0/5) | 54.5% (12/22) | 39.1% (18/46) |
| AMFm ACTsb outside API range | ||||||
| Accra | 58.3% (7/12) | 0% (0/27) | N/A | N/A | N/A | 17.9% (7/39) |
| Lagos | 0% (0/11) | 2.3% (1/44) | N/A | N/A | N/A | 1.8% (1/55) |
| Lomé | 0% (0/1) | 0% (0/9) | N/A | N/A | N/A | 0% (0/10) |
| Total | 29.2% (7/24) | 1.3% (1/80) | N/A | N/A | N/A | 7.7% (8/104) |
Notes:
a
collected antimalarial drugs lacking an AMFm logo on packaging;
b
collected antimalarial drugs displaying an AMFm logo on packaging.
Abbreviations: ACTs, artemisinin-based combination therapies; N/A, not applicable.